And your compliance issue is with respect to brand-name drugs. So how do we understand this proportionality in terms of expenditure of resources? Are the brand-name drug companies coming to you and whining that the generics are getting too much control or too much influence? What is it?
On May 12th, 2009. See this statement in context.